Received Apr 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y014305 | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | — |
No other information provided. No additional AE.; HCP calling to inform PROQUAD administration for a patient 17 years old (outside of PI). The PROQUAD was administered on 4/16/25 and patient is not symptomatic.; This spontaneous report was received from a Nurse and refers to a 17-year-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, previous drug reactions and allergies were not reported. On 16-Apr-2025 at the age of 17, the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (rHA [recombinant human albumin]) (PROQUAD) administered as prophylaxis (Lot No. Y014305 has been verified to be a valid lot number for [Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live], expiration date reported and upon internal validation established as 18 Feb 2026 (strength, dose number, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided); that was reconstituted with sterile diluent solution for injection (BAXTER STERILE DILUENT) (Lot number, expiration date, route of administration and indication was not provided) (product administered to patient of inappropriate age) No other information provided. No additional adverse event (No adverse event).